聖邦股份(300661.SZ):擬以3000萬元參與認購上海勵新投資管理中心份額
格隆匯6月17日丨聖邦股份(300661.SZ)公佈,為促進公司長遠發展,充分藉助專業投資機構的力量及資源優勢,進一步拓寬公司行業領域及提升綜合競爭力,在不影響公司日常經營及發展、有效控制投資風險的前提下,聖邦微電子(北京)股份有限公司作為有限合夥人以自有資金人民幣3000萬元參與認購上海勵新投資管理中心(有限合夥)份額。
主要投資領域:集成電路/半導體;5G;人工智能;企業服務(大數據、安全、雲計算、邊緣計算等);ABC行業應用賦能(將AI、大數據、雲計算等技術手段賦能醫療、教育、物流、電商等領域)等相關行業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.